Abstract Library

#4156 Status of the ongoing SORENTO clinical trial: Assessing efficacy and safety of high-exposure octreotide subcutaneous depot in patients with GEP-NET

Introduction: Somatostatin receptor ligands (SRLs) are first-line standard of care therapies for gastroenteropancreatic neuroendocrine tumors (GEP-NET). Retrospective data suggest higher-dose SRLs may benefit patients with GEP-NET.

Conference:

Presenting Author: Singh S

Authors: Singh S, Capdevila J, Ang Chan J, de Herder W, Grozinsky-Glasberg S,

Keywords: CAM2029, GEP-NET, high plasma exposure, octreotide, randomised active-controlled, somatostatin receptor ligands, SORENTO,

#4097 Metabolic tumor volume (MTV) as a biomarker in patients with gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): A multicentre study

Introduction: 18F-FDG PET/CT avidity predicts for higher histological grade and worse prognosis in patients with NEN. However, there is less evidence regarding the role of FDG-avid tumor volume in predicting prognosis.

Conference:

Presenting Author:

Authors: Chan D, Hayes A, Karfis I, Conner A, Mileva M,

Keywords: prognostic biomarker, PET imaging, 18F-FDG, metabolic tumor volume,

#3126 The potential role of circulating DNA in the management of neuroendocrine tumors: NET Sanguis study

Introduction: Pancreatic neuroendocrine tumors (PNETs) have variable biology, with no validated biomarkers to predict behaviour or treatment response. Circulating tumoral DNA (ctDNA) has been utilised in other cancers as a biomarker for mutation detection, drug target identification and direct change of therapy. ctDNA has been detected in patients with PNETs: its utility as a biomarker in the disease course of PNET patients has not been assessed.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Michael M

Authors: Michael M, Segelov E, Chan D, Wyld D, Price T,

Keywords: pancreatic neuroendocrine tumor, biomarker, circulating DNA,

#1893 Peripheral Blood Biomarkers of Systemic Inflammation May Be Prognostic in Metastatic Gastroenteropancreatic Neuroendocrine Tumour (GEPNET) Patients Following 177Lu-DOTATATE (LuTate)

Introduction: LuTate is a treatment for well-differentiated NETs with adequate somatostatin receptor expression. Prognostic biomarkers in this population are lacking. Neutrophil-to-lymphocyte ratio (NLR) is prognostic in the majority of solid tumours but is reported to have less value in indolent well-differentiated NETs.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Hayes A, Hosking E, Thomas D, Sjoquist K, Chan D,

Keywords: prognostic, biomarker, PRRT, LuTate,

#1505 A Blood-Based Multi-Transcript Test, the NETest, Predicts and Defines PRRT Efficacy in Neuroendocrine Tumors

Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective NET treatment. Predicting response is based on somatostatin receptor expression and efficacy evaluated by RECIST criteria. Both have limited accuracy. The NETest measures tumor activity in blood and correlates cell signaling and metabolism directly with tumor activity.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Bodei L

Authors: Bodei L, Kidd M, Severi S, Drozdov I, Nicolini S,

Keywords: NETest, PRRT,